393 related articles for article (PubMed ID: 26068969)
1. The potential utility of acetyltanshinone IIA in the treatment of HER2-overexpressed breast cancer: Induction of cancer cell death by targeting apoptotic and metabolic signaling pathways.
Guerram M; Jiang ZZ; Yousef BA; Hamdi AM; Hassan HM; Yuan ZQ; Luo HW; Zhu X; Zhang LY
Oncotarget; 2015 Sep; 6(26):21865-77. PubMed ID: 26068969
[TBL] [Abstract][Full Text] [Related]
2. A novel compound modified from tanshinone inhibits tumor growth in vivo via activation of the intrinsic apoptotic pathway.
Tian HL; Yu T; Xu NN; Feng C; Zhou LY; Luo HW; Chang DC; Le XF; Luo KQ
Cancer Lett; 2010 Nov; 297(1):18-30. PubMed ID: 20494511
[TBL] [Abstract][Full Text] [Related]
3. Acetyltanshinone IIA is more potent than lapatinib in inhibiting cell growth and degrading HER2 protein in drug-resistant HER2-positive breast cancer cells.
Huang B; Yip WK; Wei N; Luo KQ
Cancer Lett; 2020 Oct; 490():1-11. PubMed ID: 32585412
[TBL] [Abstract][Full Text] [Related]
4. Experimental study of the anti-cancer mechanism of tanshinone IIA against human breast cancer.
Lu Q; Zhang P; Zhang X; Chen J
Int J Mol Med; 2009 Dec; 24(6):773-80. PubMed ID: 19885617
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
6. A benzimidazole derivative exhibiting antitumor activity blocks EGFR and HER2 activity and upregulates DR5 in breast cancer cells.
Chu B; Liu F; Li L; Ding C; Chen K; Sun Q; Shen Z; Tan Y; Tan C; Jiang Y
Cell Death Dis; 2015 Mar; 6(3):e1686. PubMed ID: 25766325
[TBL] [Abstract][Full Text] [Related]
7. Potential anticancer activity of tanshinone IIA against human breast cancer.
Wang X; Wei Y; Yuan S; Liu G; Lu Y; Zhang J; Wang W
Int J Cancer; 2005 Sep; 116(5):799-807. PubMed ID: 15849732
[TBL] [Abstract][Full Text] [Related]
8. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
9. Development of a Liposomal Formulation of Acetyltanshinone IIA for Breast Cancer Therapy.
Wang Q; Luo M; Wei N; Chang A; Luo KQ
Mol Pharm; 2019 Sep; 16(9):3873-3886. PubMed ID: 31389706
[TBL] [Abstract][Full Text] [Related]
10. RL66 a second-generation curcumin analog has potent in vivo and in vitro anticancer activity in ER‑negative breast cancer models.
Yadav B; Taurin S; Larsen L; Rosengren RJ
Int J Oncol; 2012 Nov; 41(5):1723-32. PubMed ID: 22971638
[TBL] [Abstract][Full Text] [Related]
11. A novel anti-cancer agent, acetyltanshinone IIA, inhibits oestrogen receptor positive breast cancer cell growth by down-regulating the oestrogen receptor.
Yu T; Zhou Z; Mu Y; de Lima Lopes G; Luo KQ
Cancer Lett; 2014 Apr; 346(1):94-103. PubMed ID: 24374015
[TBL] [Abstract][Full Text] [Related]
12. Houttuyninum, an active constituent of Chinese herbal medicine, inhibits phosphorylation of HER2/neu receptor tyrosine kinase and the tumor growth of HER2/neu-overexpressing cancer cells.
Zhou NN; Tang J; Chen WD; Feng GK; Xie BF; Liu ZC; Yang D; Zhu XF
Life Sci; 2012 May; 90(19-20):770-5. PubMed ID: 22525372
[TBL] [Abstract][Full Text] [Related]
13. The anti-malarial drug artesunate causes cell cycle arrest and apoptosis of triple-negative MDA-MB-468 and HER2-enriched SK-BR-3 breast cancer cells.
Greenshields AL; Fernando W; Hoskin DW
Exp Mol Pathol; 2019 Apr; 107():10-22. PubMed ID: 30660598
[TBL] [Abstract][Full Text] [Related]
14. Tocotrienols induce apoptosis in breast cancer cell lines via an endoplasmic reticulum stress-dependent increase in extrinsic death receptor signaling.
Park SK; Sanders BG; Kline K
Breast Cancer Res Treat; 2010 Nov; 124(2):361-75. PubMed ID: 20157774
[TBL] [Abstract][Full Text] [Related]
15. Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer.
Qian J; Chen Y; Meng T; Ma L; Meng L; Wang X; Yu T; Zask A; Shen J; Yu K
Oncotarget; 2016 Oct; 7(41):67071-67086. PubMed ID: 27563814
[TBL] [Abstract][Full Text] [Related]
16. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
17. Tanshinone I effectively induces apoptosis in estrogen receptor-positive (MCF-7) and estrogen receptor-negative (MDA-MB-231) breast cancer cells.
Nizamutdinova IT; Lee GW; Son KH; Jeon SJ; Kang SS; Kim YS; Lee JH; Seo HG; Chang KC; Kim HJ
Int J Oncol; 2008 Sep; 33(3):485-91. PubMed ID: 18695877
[TBL] [Abstract][Full Text] [Related]
18. Cryptotanshinone induces cell cycle arrest and apoptosis through the JAK2/STAT3 and PI3K/Akt/NFκB pathways in cholangiocarcinoma cells.
Ke F; Wang Z; Song X; Ma Q; Hu Y; Jiang L; Zhang Y; Liu Y; Zhang Y; Gong W
Drug Des Devel Ther; 2017; 11():1753-1766. PubMed ID: 28670110
[TBL] [Abstract][Full Text] [Related]
19. Tanshinone IIA induces growth inhibition and apoptosis in gastric cancer in vitro and in vivo.
Chen J; Shi DY; Liu SL; Zhong L
Oncol Rep; 2012 Feb; 27(2):523-8. PubMed ID: 22038415
[TBL] [Abstract][Full Text] [Related]
20. An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor Xenografts.
Chen Q; Weng Z; Lu Y; Jia Y; Ding L; Bai F; Ge M; Lin Q; Wu K
PLoS One; 2017; 12(1):e0168960. PubMed ID: 28045951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
